

INNOVATIONS®



NABP Partnerships *Build Layers* of Online Safety

3 NABP Announces 2019-2020 Executive Committee Openings

10 NABP Holds Medical Marijuana Webinar

16 Travel Grant Available to Active Member Boards of Pharmacy



INNOVATIONS® table of contents

EXECUTIVE COMMITTEE

Jeanne D. Waggener
Chairperson

Susan Ksiazek
President

**Jack W. “Jay”
Campbell**
President-elect

Timothy D. Fensky
Treasurer

Bradley S. Hamilton
Member, District 1

Caroline D. Juran
Member, District 2

**Reginald B. “Reggie”
Dilliard**
Member, District 3

Philip P. Burgess
Member, District 4

Gary W. Dewhirst
Member, District 5

Lenora S. Newsome
Member, District 6

Nicole L. Chopski
Member, District 7

Richard B. Mazzoni
Member, District 8

*NABP Executive
Committee elections
are held each year at the
Association’s Annual
Meeting.*

Innovations

(ISSN 2472-6850 – print; ISSN 2472-6958 – online) is published 10 times a year by the National Association of Boards of Pharmacy® (NABP®) to educate, to inform, and to communicate the objectives and programs of the Association and its 66 member boards of pharmacy.

The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABP or any board unless expressly so stated. The subscription rate is \$70 per year.

National Association of Boards of Pharmacy

1600 Feehanville Drive, Mount Prospect, IL 60056 • 847/391-4406
www.nabp.pharmacy • help@nabp.pharmacy

Carmen A. Catizone
Executive Director/Secretary

Amy Suhajda
Communications Manager

©2018 National Association of Boards of Pharmacy. All rights reserved. No part of this publication may be reproduced in any manner without the written permission of the executive director/secretary of the National Association of Boards of Pharmacy.

NABP Mission Statement

NABP is the independent, international, and impartial association that assists its member boards and jurisdictions for the purpose of protecting the public health.


4 Policy Perspectives
Congressional Action on the Opioid Epidemic: What Was Included and Where We Go From Here

10 Association News
NABP Pilots Data Exchanges With Boards to Streamline Workflow and Licensure Processes

13 115th Annual Meeting
Proposed Resolutions Will Be Distributed in February 2019

18 State Board News
Idaho Implements Continuation of Therapy Rule

19 Professional Affairs Update
FDA’s Final Guidances Address Compounding and Repackaging of Radiopharmaceuticals



Feature News
NABP Partnerships Build Layers of Online Safety



115th Annual Meeting
Minneapolis-Bound: Take in the ‘City of Lakes’

NABP Announces 2019-2020 Executive Committee Openings; Elections to Take Place at Annual Meeting

Officers and members of the 2019-2020 NABP Executive Committee will be elected in May 2019 during the 115th Annual Meeting in Minneapolis, MN. Open officer positions include president-elect and treasurer. The open member positions are for Districts 1, 2, 3, and 5.

The treasurer serves a one-year term, while the individual selected as president-elect makes a three-year commitment to the Association. Following one year as president-elect, he or she serves one year as the NABP president before assuming the responsibilities of chairperson of the Executive Committee for the final year.

Officer Nominations

Individuals interested in running for an open officer position must submit a letter of intent, including the expiration date for their term on the active member board, along with a résumé or curriculum vitae, to the NABP executive director/secretary at least 45 days prior (**by April 1, 2019**) to the Annual Meeting's First Business Session.

At press time, NABP has received the following nominations for the open officer positions:

President-elect (one-year term)

- Timothy D. Fensky, RPh, DPh, FACA, Massachusetts

Treasurer (one-year term)

- Reginald B. "Reggie" Dilliard, DPh, Tennessee
- Caroline D. Juran, RPh, DPh, Virginia

Member Nominations

Each district has the opportunity to nominate up to two candidates at the

respective district meetings. At press time, districts have nominated the following candidates for the Executive Committee member positions:

District 1 (three-year term)

- Bradley S. Hamilton, RPh, Maine

District 2 (three-year term)

- Tejal Patel, MBA, PharmD, RPh, Delaware
- Cynthia L.W. Warriner, RPh, CDE, Virginia

District 3 (one-year term)

- Jeffrey J. Mesaros, PharmD, JD, RPh, Florida

District 5 (three-year term)

- Diane M. Halvorson, RPhTech, CPhT, North Dakota
- Shane Wendel, PharmD, RPh, North Dakota

In addition to the nominations made by the districts for the open member positions, individuals may seek to become a candidate by providing written notice to the NABP executive director/secretary. The written notice must include a letter of intent, the expiration date for their term on the active member board, and a résumé or curriculum vitae. Written notice must be submitted after the relevant district meeting and received no later than 45 days prior (**by April 1, 2019**) to the Annual Meeting's First Business Session, as stated in Article IV, Section 3(c)(ii) of the NABP Constitution and Bylaws. Only those individuals who have been determined by NABP to meet all qualifications for the open member positions will be placed on the ballot.

At press time, no candidate submissions had been received.

Qualifications and Voting Procedures

Candidates for open Executive Committee officer and member positions must meet the following criteria:

- must be an affiliated member (administrative officer or board member) of the Association currently serving on a board of pharmacy of an active member state at the time of nomination and election.
- must not, in addition to his or her board of pharmacy activities, currently serve as an officer, official, or board or staff member for any national or state pharmacy organization.
- must not have a conflict of interest with the purpose, mission statement, and operation of NABP.

During the First Business Session of the Annual Meeting, NABP President Susan Ksiazek, RPh, DPh, will announce the candidates for the open Executive Committee officer positions and the nominees selected by the districts for the open member positions. The president will also announce any additional candidates who have submitted the required materials to run for office by the specified deadlines and have been qualified by NABP. The final ballot for the Executive Committee election will include all the individuals announced during the First Business Session.

During the Annual Meeting, time will be designated for candidate speeches

continued on page 6

Congressional Action on the Opioid Epidemic: What Was Included and Where We Go From Here



Libby Baney, JD,
Faegre Baker Daniels Consulting

After a year-long policy development process, Congress came together with a bipartisan, bicameral legislative package to address the opioid epidemic facing our nation. Both the United States House of Representatives and the US Senate passed HR 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, which was signed into law by President Donald J. Trump on October 24, 2018.

This legislation comes on the heels of previous Congressional efforts to address the opioid epidemic, including the passage of the Comprehensive Addiction and Recovery Act in July 2016 and the 21st Century Cures Act in December 2016, and over \$3 billion in appropriated funds, primarily to support medication-assisted treatment services (MAT), from the fiscal year 2018 omnibus spending package.

The SUPPORT Act covers a broad range of areas related to the opioid epidemic, and multiple federal agencies are affected, including the Centers for Medicare & Medicaid Services, Food and Drug Administration (FDA), Department of Justice (DOJ), Drug Enforcement Administration (DEA), and the Centers for Disease Control and Prevention (CDC). Some provisions create new funding opportunities, some reauthorize existing funding streams, and others make policy changes, such as new requirements for states, providers, and pharmacies. It is important to note that while the Act does authorize some spending for the opioid epidemic, the funding will not reach the federal agencies to then

allocate to states and local entities until Congress follows up with appropriations through the annual spending process.

The SUPPORT Act contains a variety of provisions that will or may affect state boards of pharmacy. These provisions include new authorities and/or funding related to prescription monitoring programs (PMPs), counterfeit drugs and trafficking enforcement, DEA authorities to prevent diversion, pharmacy regulation, telemedicine, and prescribing.

Prescription Monitoring Program Provisions

As discussed in the October 2018 issue of *Innovations*, NABP was successful in working closely with members of Congress to ensure that a policy was not put in place to require an unnecessary and misguided new national PMP system, which would have undermined the good work that states are already doing to share data via the NABP PMP InterConnect[®] system. Instead, Congress authorized nearly \$500 million in CDC grants to expand evidence-based addiction prevention, explicitly including efforts to improve the efficiency and use of a new or currently operating PMP.

The SUPPORT Act includes additional PMP policies, all of which include deference to state law and are consistent with PMP InterConnect. The Act:

- clarifies state Medicaid programs' and Medicaid managed care organizations' ability to access and share data from PMPs in accordance with state law;
- requires Medicaid providers to check PMPs in accordance with timing, manner, and form, as specified by the state. This policy encourages states to develop PMPs that are real time and facilitate integration into provider workflow; and



Megan S. Herber, MPH,
Faegre Baker Daniels Consulting

- requires the federal government each year to support states and localities for the purpose of improving efficiency and use of PMPs, including clinical workflow and health internet technology infrastructure integration.

Counterfeit Drug and Trafficking Enforcement Provisions

The SUPPORT Act includes a version of the Synthetics Trafficking and Overdose Prevention (STOP) Act, championed by Senators Amy Klobuchar and Rob Portman and former Representative Patrick Tiberi and Representative Richard E. Neal. NABP supported the STOP Act as it moved through Congress. This provision requires that shipments coming from foreign countries into the US postal system provide electronic advance data before the shipments enter the US in an effort to help combat illegal drug shipments from overseas.

The SUPPORT Act also includes provisions intended to provide FDA with more resources, tools, and authority to prevent illegal drug products from entering the US supply chain from overseas via mail, something NABP also supports.

Related to this, in October 2018, the US Postal Service Office of Inspector General issued a new report urging the Postal Service to work closely with Congress to deter online drug traffickers from using its networks to ship deadly illicit opioids into the US. Among other startling facts, the Inspector General report found that 80% of the surface web (not dark web) that offers instructions on how to ship illicit drugs to the US suggest using the US Postal Service. Future *Innovations* issues may discuss this topic in more detail.

DEA and Diversion Provisions

As boards of pharmacy well know, DEA's mission is to prevent the illicit use of controlled substances (CS). This

includes ensuring that opioids are only used for appropriate legitimate medical purposes. The SUPPORT Act gives DEA additional tools to accomplish this mission through various points of the supply chain, from manufacturer to distributor/wholesaler to pharmacy to patient. The Act includes provisions that would:

- require DEA to provide drug manufacturers and distributors with access to anonymized Automation of Reports and Consolidated Orders System data to determine the total quantity of opioids being delivered to pharmacies;
- require DEA to consider diversion, abuse, overdose deaths, and public health impacts when setting opioid quotas;
- clarify the definition of suspicious orders and centralize data in order to improve and expand manufacturer reporting of suspicious orders to DEA; and
- provide additional DOJ funding for five states to further participate in DEA National Prescription Drug Take Back Day.

Other Provisions Related to Prescribing or Pharmacies

There are a handful of additional Provisions in the Act that will affect pharmacies, pharmacists, and prescribers.

In the Medicare program, new rules will be imposed requiring e-prescribing for CS as well as e-prior authorization.

Of particular interest to pharmacies, under the law, prescription drug plans will be able to suspend payments pending investigations of credible allegations of fraud by pharmacies. Another provision would allow pharmacies to dispense implantable or injectable CS directly to providers,

rather than requiring the patient to pick them up from the pharmacy.

Of particular interest to pharmacists, the legislation requires the federal government to develop guidance and training on when pharmacists may decline to fill a prescription for CS due to suspicion of fraud or diversion.

As for prescribers and clinicians, the Act reauthorizes the State Targeted Response grants aimed at increasing access to MAT services as well as provisions to encourage the use of telemedicine for prescribing MAT.

What's Next?

Now that this complex legislation has been passed into law, the agencies affected will be tasked with fleshing out and implementing its provisions. This will happen with input from stakeholders, including NABP, states, and state boards of pharmacy.

Certainly, many members of Congress have claimed victory in the fight against the opioid epidemic during their November 2018 election campaigns, but those on the ground know that much more work is left to be done. There are many pieces of legislation addressing the epidemic championed by members of Congress that did not make it into this final bill. It is likely that those champions will continue to push for more Congressional action, such as more insight into data around opioid orders or more funding for prevention and treatment activities, but it remains to be seen what the 116th Congress starting in January will choose to prioritize.

This article was written by Libby Baney, JD, and Megan S. Herber, MPH, both with Faegre Baker Daniels Consulting. Please note, the opinions and views expressed by Faegre Baker Daniels Consulting do not necessarily reflect the official views, opinions, or policies of NABP or any member board unless expressly stated. ■

Open Positions

continued from page 3

and/or speeches given on behalf of the candidates for open Executive Committee officer and member positions. Individuals giving candidate speeches must be affiliated members of NABP, and a maximum of two speeches may be given for each candidate, including the candidate's own speech. Individuals giving speeches must limit their remarks to two minutes.

Voting will take place during the Final Business Session. Candidates, whether running opposed or unopposed, must receive a majority of the delegate votes present in order to be elected to office. If more than two candidates are slated for office, the candidate(s) receiving the fewest votes will be eliminated

“The results of the election will be announced immediately, followed by an installation ceremony for the new officers and members of the 2019-2020 Executive Committee, whose terms commence at once.”

from subsequent ballots. The results of the election will be announced immediately, followed by an installation ceremony for the new officers and members of the 2019-2020 Executive Committee, whose terms commence at once.

More information about the procedures for nominating and electing Executive

Committee officers and members is available in Article IV, Sections 3(b) and 3(c) of the NABP Constitution and Bylaws. Updates to the list of nominees will be posted in the About section of the NABP website at www.nabp.pharmacy. More information on the 115th Annual Meeting is available on pages 12 to 16. ■

Volunteers Convene in Fall 2018 to Review and Write Exam Items for the NAPLEX



(Above, left to right) Michelle Musser, PharmD, RPh, BCPS, Ohio Northern University College of Pharmacy, and Winter Smith, PharmD, RPh, BCPS, Texas Tech University Health Sciences Center, reviewed items for the North American Pharmacist Licensure Examination® (NAPLEX®) on September 19-21, 2018.



(Above, left to right) David Hutchinson, PharmD, RPh, St John Fisher College, and Justin Kullgren, PharmD, CPE, RPh, The Ohio State University Wexner Medical Center, James Cancer Hospital, were among the NAPLEX volunteer item writers present on September 19-21, 2018.

Task Force to Develop Regulations Based on Standards of Care Convened in October 2018



The Task Force to Develop Regulations Based on Standards of Care met in October 2018 at NABP Headquarters to explore the feasibility of transitioning from prescriptive, rule-based regulations to a model that defines regulation through a standard of care process. Task force members pictured are (front, left to right) Kristen Snair, CPhT, Arizona State Board of Pharmacy; Carrie Phillips, MS, PharmD, RPh, Vermont Board of Pharmacy; Kristina Jonas, PharmD, RPh, Idaho State Board of Pharmacy; Donna Horn, RPh, DPh, Massachusetts; Cindy Fain, PD, Arkansas State Board of Pharmacy; Edmund Taglieri, MSM, NHA, RPh, Massachusetts Board of Registration in Pharmacy; Donna S. Wall, PharmD, RPh, Indiana Board of Pharmacy; Maureen Cahill, MSN, RN, APN-CNS, National Council of State Boards of Nursing; (back, left to right) Bradley S. Hamilton, RPh, NABP Executive Committee liaison; Donnie Lewis, RPh, Texas State Board of Pharmacy; Allison Vordenbaumen Benz, MS, RPh, Texas State Board of Pharmacy; Robert Graves, North Carolina Board of Pharmacy; Stuart Williams, JD, Minnesota Board of Pharmacy; Andrew Funk, PharmD, RPh, Iowa Board of Pharmacy; Ian Marquand, CMBE, Federation of State Medical Boards; Lemrey “Al” Carter MS, PharmD, RPh, Illinois Department of Financial and Professional Regulation, Division of Professional Regulation – State Board of Pharmacy; and Daniel Robinson, PharmD, FASHP, American Association of Colleges of Pharmacy. ■

NABP Seeks Committee and Task Force Volunteers

NABP is seeking volunteers from its active member boards of pharmacy to serve on committees and task forces during the 2019-2020 period. Executive officers and current board members, including public members, interested in serving on a committee or task force are encouraged to submit an application and an up-to-date résumé or curriculum vitae.


Board of pharmacy staff interested in volunteering for NABP task forces are also encouraged to apply.

Please send applications to NABP Executive Director/Secretary Carmen A. Catizone at NABP Headquarters or ExecOffice@nabp.pharmacy by **Friday, June 7, 2019**. All materials will be forwarded to NABP President-

elect Jack W. “Jay” Campbell IV, JD, RPh, who will make the appointments following NABP’s 115th Annual Meeting.

A link to the online interest form is available on the Task Force Reports page in the Publications and Reports section on the NABP website at www.nabp.pharmacy. ■

NABP Partnerships *Build Layers* of Online Safety



Internet safety as it pertains to pharmacy has come a long way in recent years, with NABP at the forefront of many related endeavors. NABP's .Pharmacy Verified Websites Program has created an entire web domain that contains only verified, legitimate online pharmacies and pharmacy-related websites. Major search engines and social media sites have developed advertising policies intended to allow only legitimate, legally operated entities to appear on consumers' screens as sponsored search results or social media advertisements. Despite these positive steps, the internet remains a place where consumers can

all too easily purchase medications (often counterfeit) from unscrupulous vendors and where false information spreads virally – in short, a place where the public health is deeply threatened.

“Advertising policies implemented by Google, Bing, Yahoo!, Twitter, and Snapchat requiring NABP website verification represent an important victory in combating illegal behavior, but one that is limited; other approaches are simultaneously required.”

Advertising policies implemented by Google, Bing, Yahoo!, Twitter, and Snapchat requiring NABP website verification represent an important victory in combating illegal behavior, but one that is limited; other approaches are simultaneously required. Encouragingly, two major companies have launched efforts in recent months tackling the problem from different angles. Credit card giant Visa has launched a policy requiring all pharmacies that process “card not present” transactions to obtain reputable third-party certification that they are operating legally. Meanwhile, search engine Bing (owned by Microsoft) is piloting a program that uses NABP’s extensive investigation of online pharmacies to warn consumers when their organic search results include sites that appear on NABP’s “Not Recommended” pharmacy list.

Visa: Legitimate Sales Only

Credit card giant Visa is tackling the illegal pharmacy problem by limiting the use of Visa credit cards to legitimate pharmacy businesses. The company requires its “acquirers” – the complex network of payment processors and/or banks that underwrite merchants and make it possible for them to accept Visa-brand credit cards – to ensure that the pharmacy merchants with which they have contracted are certified legitimate pharmacies. The potential impact of this policy is substantial. According to one study, more than 40% of consumers feel credit cards are the safest online payment method, and between 19 million and 26 million people in the US alone purchase medicines over the internet, according to World Health Organization estimates. In a 2018 survey, the Alliance for Safe Online Pharmacies found that one in three Americans have purchased prescription medication over the internet.

Visa’s goal is to ensure that its credit card brand is not used in illegal transactions, or in facilitating transactions that endanger public health and safety. In order

to onboard a merchant that runs a business more prone to these types of abuses, including pharmacies, an acquirer must obtain High-Risk Brand Acquiring License from Visa; when adding these merchants to their networks, the acquirers take responsibility for vetting the merchants and vouching for their ongoing behavior. In 2017, Visa updated its policies to require third-party certification and monitoring for pharmacy merchants that conduct card-not-present transactions, including those conducted online or via mail order, or telephone. Pharmacies with an internet presence may obtain certification through NABP's .Pharmacy Program, Verified Internet Pharmacy Practice Sites® (VIPPS®), or Verified-Accredited Wholesale Distributors® program; NABP is one of only two recognized certifiers under the new rules. Prior to this update, merchants could demonstrate their legitimacy to acquirers either through a third-party verifier, including NABP, or via a lawyer's letter. (Credit card brand Mastercard, which likewise recognizes NABP as a third-party verifier, still follows this model.)

In addition to serving as a third-party verifier for pharmacy merchants, NABP has entered into a collaboration with G2 Web Services, a company that offers risk management services to banks and other payment processing businesses (and a member of the Alliance for Safe Online Pharmacies). Through this partnership, NABP is educating G2 customers about illegal online drug selling and helping them distinguish between rogue drug selling and legitimate pharmacies. Over the past year, NABP has participated in G2-sponsored webinars reaching hundreds of payment processing stakeholders that have pharmacy merchants as customers. In 2019, NABP will continue this educational campaign through presentations at G2 Merchant Risk Summits, Merchant Acquirers Committee (MAC) webinars, and a Vendor Spotlight at the MAC Annual Conference.

NABP Collaborating With Search Engines to Increase Online Safety

NABP has collaborated with Bing to increase online safety for nearly a decade. In 2010, Bing began requiring pharmacies that advertise on the search engine to be accredited through NABP, initially via the VIPPS program and, later, the .Pharmacy Program. In 2015, the search engine added a consumer safety element to its "organic" search results (those results not linked to paid advertisers but that most closely match the terms used in a search query, based on relevance), causing a pop-up warning box to appear if a Bing user clicks on a website identified by the United States Food and Drug Administration (FDA) as a fraudulent pharmacy engaged in illegal activity. While the pop-up warning does not prevent users from clicking through to the site, it does inform them that the site in question has received an FDA Warning Letter and might offer unsafe drugs, and recommends the user select another result. It also offers a link to find out more information about safe online purchasing. Bing reports that the pop-up warnings are effective and consumers typically do not click through to websites that are accompanied by the pop-up.

While encouraging, this novel approach to adding valuable consumer safety information to the organic search process has had limited reach, as FDA has issued warning letters to only a small fraction of the estimated 30,000 illicit pharmacies operating online. Bing is now determining how it can use additional NABP resources to scale up the program. In October 2018, the search engine began displaying similar pop-up warnings to appear if a Bing user hovers over a link or attempts to click on a website that appears on NABP's extensive Not Recommended List of internet drug outlets that appear to be operating out of compliance with state and federal laws or NABP patient-safety and pharmacy practice standards.

In 2018, more than 11,000 websites appeared on this continuously updated list, greatly increasing the scope and the potential effect of the program. At press time, Bing was still considering the effect of the pilot.

Social Media Sites Join the Fight Against Rogue Pharmacies

NABP has also been working with social media companies and other stakeholders to protect consumers from fake pharmacies. Snap, Inc, a technology and camera company, updated its advertising policy related to online pharmacies. In the United States and Canada, an online pharmacy must be verified by NABP in order to advertise on Snap's mobile app, Snapchat. Over 180 million people use Snapchat every day; the core user demographic includes teenagers as young as 13. Snapchat joins Twitter and search engines Google, Bing, and Yahoo! in requiring that pharmacy-related advertisers obtain NABP verification.

In addition, the Association shared the results of an NABP study related to social media sites leading consumers to dangerous rogue pharmacy sites with representatives from Pinterest. Pinterest said it is aware of the problem and is taking steps to further reduce the number of illicit Pins that slip through its filters. Additional information on this study was provided in the September 2018 *Internet Drug Outlet Identification Program Progress Report for State and Federal Regulators*, available on the Program and Committee Reports page in the Publications and Reports section at www.nabp.pharmacy.

Online pharmacy safety is a complex issue requiring a multipronged approach by all stakeholders. The Bing and Visa initiatives, both of which tap into the resources and expertise housed in NABP's .Pharmacy Program, each have potential to advance the Association's public health safety goals. ■

NABP Pilots Data Exchanges With Boards to Streamline Workflow and Licensure Processes

NABP is working with several state boards of pharmacy to ensure that the data entered into its e-Profile Connect system is accurate, up to date, complete, and more quickly accessible to the boards. As part of this pilot project, several boards have provided NABP with licensee information that NABP will use to match e-Profiles in its system. Following this, NABP has created an application programming interface, a universal method by which any board will be able to exchange information with NABP, regardless of how they

format data within their own systems. This will reduce the need to manually input and verify data and reduce the overall processing time for boards. The new process will also reduce the amount of incorrect or incomplete information finding its way into NABP's databases, further decreasing application processing time for the boards.

Boards of pharmacy can expect to see several other benefits from the new process in the future. Ultimately, they will no longer be required to log in to

e-Profile Connect to search for and key in information to communicate certain things – like license number – to NABP. In addition, boards will not be required to log in to the system to download examination scores. They will download automatically. These automated processes are expected to increase information flow and streamline workflow processes for the boards of pharmacy.

More information about NABP's data exchange project will be available in future issues of *Innovations*. ■

NABP Holds Medical Marijuana Webinar

While federal laws and regulations consider marijuana a Schedule I drug under the Controlled Substances Act, United States jurisdictions have been establishing state medical marijuana programs and officially recognizing marijuana for recreational use. As state departments of public health and state boards of pharmacy begin to encounter cases associated with medical or recreational marijuana use among licensees, NABP presented a webinar to explore the issue further and gain insight on states' perspectives. Held via live webinar on October 11, 2018, guest speakers provided insight about state approaches to licensee discipline for medical or recreational marijuana use as well as clinical information about the side effects, impairment, and drug screening of marijuana use.

The guest speakers who led the discussions during the interactive webinar – titled "Disciplinary Cases and Marijuana: Regulatory and Clinical Overview" – included Krista Batchelder, assistant attorney general for the Colorado Board of Pharmacy; Kimberly Grinston, executive director of the Missouri Board of Pharmacy; and Dr Frank Paloucek, clinical professor and director of the Pharmacy Residency Program at University of Illinois at Chicago.

At the invitation-only webinar, attendees (such as state board of pharmacy executive officers, legal counsel, and compliance officers) engaged with the moderators during a live "Questions and Answers" session. Participants could earn continuing pharmacy education credit for this opportunity sponsored by NABP. Future webinars will be communicated to boards through executive officers. ■

Third Quarter 2018 NABP Clearinghouse Totals

During the third quarter of 2018, the state boards of pharmacy reported approximately 2,640 disciplinary actions to the NABP Clearinghouse. The majority of actions were taken against pharmacists, pharmacies, and pharmacy technicians.

The three disciplinary actions most reported during third quarter 2018 were publicly available fine/monetary penalty (920 actions or 34.8%); other actions not classified (380 actions or 14.4%); and reprimand or censure (216 actions or 8.2%).

Of the 1,804 bases for actions cited in third quarter 2018, other bases for actions not classified (244 bases or 13.5%); failure to comply with continuing education or competency requirements (236 bases or 13.1%); and violation of federal or state statutes, regulations, rules or state health code (218 bases or 12.1%) were the top reasons why disciplinary actions were taken during the period.

As stated in the NABP Constitution and Bylaws, participation in the NABP Clearinghouse is required as part of a board of pharmacy's membership to the Association. Timely reporting to the NABP Clearinghouse is essential to maintaining the integrity of the licensure transfer program. Boards may access the Clearinghouse using NABP e-Profile Connect. ■

Forty-Eight PMPs Participate in Interstate Data Exchange via NABP PMP InterConnect


Forty-six states and two jurisdictions are now participating in interstate data exchange via NABP PMP InterConnect®, with Puerto Rico being the latest jurisdiction to connect in November 2018. NABP continues to work with other states to facilitate their participation in the program. PMP InterConnect is a highly secure communications exchange platform that facilitates the transmission of prescription

monitoring program (PMP) data across state lines to authorized PMP users, while ensuring



that each state's data access rules are enforced. Additional information about PMP InterConnect is available in the Initiatives section of the NABP website at www.nabp.pharmacy. ■

PMP InterConnect Participation Overview





Boards of Pharmacy & NABP
WORKING TOGETHER AS
A TEAM MAKES

ANYTHING POSSIBLE

NABP 115th Annual Meeting • May 16-18, 2019 • Minneapolis, MN

Schedule of Events

Wednesday, May 15, 2019

5 - 7 PM

Registration Desk Open

Thursday, May 16, 2019

7 AM - 5 PM

Registration Desk Open

7:30 - 8:30 AM

From District Meeting to Annual Meeting - Learning About NABP

8:30 - 11:30 AM

Hospitality Brunch and Educational Table Top Displays

9 - 11 AM

Educational Poster Session CPE

Noon - 3:30 PM

First Business Session

- Welcome Remarks
- Keynote Address
- Greeting From the Host State
- Report of the Executive Committee
- President's Address
- Announcement of Candidates for Open Executive Committee Officer and Member Positions

4 - 5 PM

CPE Session

6 - 9 PM

President's Welcome Reception

Friday, May 17, 2019

7 AM - 3:30 PM

Registration Desk Open

7 - 9:30 AM

NABP Breakfast

7:30 - 9 AM

NABP AWAR_xE Fun Run/Walk

9:30 - 10:30 AM

CPE Session

10:45 - 11:45 AM

CPE Session

1 - 3 PM

Second Business Session

- Report of the Treasurer
- Report of the Executive Director/Secretary
- Report of the Committee on Resolutions
- Report of the Committee on Constitution and Bylaws
- Candidate Speeches for Open Executive Committee Officer and Member Positions

3 - 3:30 PM

Informal Member/Candidate Discussions

Saturday, May 18, 2019

7 - 11 AM

Registration Desk Open

7 - 8 AM

NABP Continental Breakfast

8:30 - 11:30 AM

Final Business Session

- Election and Installation of the 2019-2020 Executive Committee Officers and Members
- Remarks of the Incoming President
- Final Report of the Committee on Constitution and Bylaws
- Final Report of the Committee on Resolutions
- Invitation to the 2020 Annual Meeting

12:45 - 2:30 PM

Annual Awards Luncheon

Note: The 115th Annual Meeting schedule is subject to change. The final schedule will be posted on the Annual Meeting website prior to the meeting.



The knowledge-based continuing pharmacy education (CPE) sessions presented at the Annual Meeting are developed specifically for the Association's member boards of pharmacy, which are composed of executive officers, board staff, board members, compliance staff, and board counsel. Sessions are also relevant to other attendees in the practice of pharmacy. By actively participating in the meeting's CPE programming, at the conclusion of the Annual Meeting participants should be able to:

- Identify the latest legislative and regulatory issues being addressed by the state boards of pharmacy.
- Explain how the changing regulatory environment impacts the state boards of pharmacy and the practice of pharmacy.
- Identify gaps in regulatory oversight and best practices for state pharmacy boards to overcome them.
- Discuss emerging roles of pharmacists and pharmacy technicians with respect to the public's access to quality health care.
- Discuss how poster session research findings further the protection of the public health.
- Describe best practices for regulating pharmacist care services in a changing health care environment.
- Analyze licensing standards between state boards of pharmacy.

Contact NABP Professional Affairs staff at 847/391-4406 or via email at Prof-Affairs@nabp.pharmacy for more details.

NABP and NABP Foundation® are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of CPE. ACPE provider number: 0205. Learning objectives and descriptions for each CPE session will be available on the CPE page of the Annual Meeting website. Instructions for claiming CPE credits, including continuing legal education credits, will also be provided.

Proposed Resolutions Will Be Distributed in February 2019

Proposed resolutions received at NABP Headquarters by Friday, February 8, 2019, will be distributed electronically to state boards of pharmacy on the following Thursday, February 14, 2019, for review prior to the 115th Annual Meeting. This mailing will constitute the only preconference distribution of proposed resolutions. All resolutions – those distributed for early review as well as those received after February 8 – will be presented to the voting delegates during the Second Business Session of the Annual Meeting by the chair of the Committee on Resolutions and subsequently voted on at the Final Business Session.


Any active member board, district, or committee of the Association may submit resolutions to NABP. To be

considered during the Annual Meeting, resolutions must be received by Friday, April 26, 2019, in accordance with Article IV, Section 6, Part (d) of the NABP Constitution and Bylaws. Resolutions not submitted at least 20 days prior to the Annual Meeting, but submitted within a time frame that the Executive Committee deems appropriate (prior to the meeting of the Committee on Resolutions), may be presented during the Annual Meeting and will be considered for adoption by the Association upon the affirmative vote of three-fourths (3/4) of those active member boards present and constituting a quorum.

Questions regarding resolution procedures should be directed to the NABP Executive Office via email at ExecOffice@nabp.pharmacy. ■

Important Deadlines

- **February 8, 2019** – Proposed resolutions must be received at NABP Headquarters for preconference distribution to the state boards of pharmacy.
- **February 14, 2019** – Proposed resolutions are distributed electronically to state boards of pharmacy for review.
- **April 26, 2019** – Proposed resolutions must be submitted to be considered at the Annual Meeting.



Online Registration Coming Soon!

Online registration for the 115th NABP Annual Meeting will be available soon on the Annual Meeting website.

Minneapolis-Bound: Take in the ‘City of Lakes’ During NABP’s 115th Annual Meeting



Weisman Art Museum photo courtesy of Meet Minneapolis

NABP invites its members and fellow stakeholders in the pharmacy community to attend its 115th Annual Meeting in the “City of Lakes” – Minneapolis, MN. This year’s theme is “Working Together as a Team Makes Anything Possible,” and the meeting will be held May 16-18, 2019, at the Minneapolis Marriott City Center.

Marvelous Minneapolis

Minneapolis was incorporated as a city in 1867 and now has the third largest economy in the Midwest. Along with St Paul, MN, it is commonly referred to as the “Twin Cities.” Minneapolis was named by the town’s first schoolmaster who combined the Greek word for city (*polis*) with the Dakota Sioux word for water (*mni*), a reference to the Mississippi River, a 53-foot-tall waterfall, and 13 lakes located in the city.

Historically, the region surrounding Minneapolis has been known for successfully farming grain, which in turn led to Minneapolis becoming a place for grain milling and flour production and a worldwide innovator and leader in these industries.

Minneapolis has developed into a forward-looking city that is a hub for culture, business, education, and nature preservation. For example, the city has been home to well-known musical artists, such as Bob Dylan and Prince. Minnesota is also a launchpad for business. The state has 19 Fortune 500 companies, many of which call Minneapolis and the surrounding region home, including Target, General Mills, Best Buy, and UnitedHealth Group.

Minneapolis’ abundance of natural bodies of water help contribute to the staggering amount of natural green space in the city. Approximately 15% of Minneapolis is city parks – the city park developer’s goal was to “establish a park within walking distance of every child in the city.” One of the city’s most popular green spaces is Minnehaha Regional Park, a recreation destination where visitors can bike, walk, explore historic buildings, and visit the park’s namesake, Minnehaha Falls.

The University of Minnesota in Minneapolis is the nation’s sixth-largest public four-year university. It boasts many highly ranked academic programs, including the school of pharmacy, which is ranked second in the country.

Making the Most of Minneapolis

Nicollet (formerly known as Nicollet Mall) is Minneapolis’ main shopping, entertainment, and dining zone, and it is situated steps from the Marriott. The area is filled with public art, the most famous example being a statue of Mary Tyler Moore from the classic *Mary Tyler Moore Show*, which was set in Minneapolis.

“Minneapolis has developed into a forward-looking city that is a hub for culture, business, education, and nature preservation.”

Nicollet offers access to the Mississippi River and the surrounding natural area. It connects to the Walker Art Center (the city's modern art museum) and the Minneapolis Sculpture Garden, which is home to Minneapolis' iconic *Spoonbridge and Cherry* sculpture. If you are strolling through Nicollet at night, be sure to check out the "Light Walk," a stretch of pedestrian path that cycles through geometric LED light displays.

Minneapolis is known as a very walkable, pedestrian-friendly city – there are also bike rental stations throughout the city called Nice Ride, with many dock stations near the Marriott.

The city continues to channel its musical past by supporting a lively music scene, where it is possible to see live music of all genres in venues ranging from stadiums to smaller, more intimate settings. Prince fans can visit Paisley Park, a music studio that also contains exhibits dedicated to Prince's life and career. For Bob Dylan fans, there is a kaleidoscope-like mural featuring the artist located in downtown Minneapolis on the corner of 5th Street and Hennepin Avenue.

The largest park in the downtown area, Loring Park, is located one mile from the Marriott. Fort Snelling, a designated National Historic Landmark located next to Minneapolis' airport, was used as a military fort throughout the frontier era and during World War II, when it was used to house and train American soldiers.

The Mall of America is the largest mall in the country – it is located in the Minneapolis area and features more than 520 stores. However, the Mall of America offers more than just shopping; visitors can also ride a roller coaster, test drive a Tesla, explore the Minnesota



Photo courtesy of the Mall of America and Meet Minneapolis

Aquarium, or build something in the Lego Imagination Center. The METRO Blue Line connects the Mall of America with the Minneapolis Airport and the downtown area.

The greater Minneapolis area is home to 55 museums. The Weisman Art Museum features a wide range of art and is housed in a spacey, futuristic-looking building. The Mill City Museum is filled with interactive exhibits that focus on how the Mississippi River and flour production helped build Minneapolis into the city it is today. There is also the Science Museum of Minnesota, which has a world-recognized fossil collection, and the Bell Museum, Minnesota's official museum of natural history that was recently revamped to include a planetarium.

More information on the meeting, transportation, and instructions on how to register will be available on the 115th Annual Meeting website. ■

Discover Minneapolis

- **Meet Minneapolis**
<https://www.minneapolis.org>
- **Lonely Planet-Minneapolis**
<https://www.lonelyplanet.com/usa/great-lakes/minneapolis>
- **Walker Art Museum**
<https://walkerart.org>
- **Mill City Museum**
<http://www.mnhs.org/millcity>
- **Mall of America**
<https://www.mallofamerica.com/home>
- **Minneapolis Parks**
<https://www.minneapolisparcs.org>

Now Accepting Proposals for Educational Poster Session

Limited Spots Available - Don't Delay!

NABP is seeking proposals for its annual Educational Poster Session. Proposed posters should reflect the overall theme of "The Value of Teamwork to Protect Public Health." Board of pharmacy members and staff, as well as schools and colleges of pharmacy, are invited to submit their proposals as they relate to this year's poster session theme. Poster proposals may be descriptive, scientific, or informational in nature. Possible topics include policy development, public health initiatives, and legislative issues, among others. Those interested in submitting a proposal should contact NABP Professional Affairs staff via email at Prof-Affairs@nabp.pharmacy for detailed instructions. Proposals must be submitted by **Wednesday, February 27, 2019**.

Proposals may only be submitted by individuals who will be available to

present the poster in Minneapolis, MN, if selected. Selected poster presenters must be available in March and April for correspondence with NABP staff and to submit required materials.

Students are welcome to submit poster proposals. If selected, the student(s) must be accompanied by a credentialed advisor or licensed pharmacist. All participating pharmacy school students will receive a complimentary voucher in their NABP e-Profile valued at \$65 to take the Pre-NAPLEX[®], a practice examination for students preparing for the North American Pharmacist Licensure Examination[®] (NAPLEX[®]).

The Poster Session will be held the morning of **Thursday, May 16, 2019**, at the NABP 115th Annual Meeting.

Poster Session presenters may be eligible to earn Accreditation Council



The NABP Educational Poster Session is an annual favorite among Annual Meeting attendees.

for Pharmacy Education-accredited continuing pharmacy education credit. Details will be provided to individuals who are selected to present posters.

Questions regarding poster proposals should be directed to NABP Professional Affairs staff via email at Prof-Affairs@nabp.pharmacy. ■

Travel Grant Available to Active Member Boards of Pharmacy

The NABP Foundation[®] is once again offering active member state boards of pharmacy travel grant opportunities to attend the NABP 115th Annual Meeting. One grant will be awarded to a current board member or administrative officer of each active NABP member board of pharmacy, as designated by the board's administrative officer, and will provide reimbursement for travel expenses, including travel, hotel rooms, meals, taxis, parking, and tips.

Eligible individuals can receive up to \$1,500 in grant monies to attend. The grant does not include registration fees. All applicants will be informed of whether they have qualified for the grant.

The grant was established to assist boards in sending voting delegates to the Annual Meeting, so they may participate in important business, including discussing and voting upon resolutions and amendments to the NABP Constitution and Bylaws, electing NABP Executive Committee officers and members, and attending educational sessions regarding current issues facing pharmacy regulators.

Last year, 41 state boards of pharmacy applied and were approved for the NABP 114th Annual Meeting Travel Grant. For more information on the Annual Meeting Travel Grant, contact the NABP Executive Office at ExecOffice@nabp.pharmacy. ■

How to Apply for the Travel Grant

- Grant applications may be obtained from NABP upon the direct requests of executive officers of the state boards of pharmacy.
- To receive reimbursement, boards must have a voting delegate in attendance at the Annual Meeting to vote during all applicable business sessions.
- Completed applications can be submitted by email to ExecOffice@nabp.pharmacy or via mail to NABP Headquarters.
- NABP requests that applications be submitted prior to the Annual Meeting.

Around the Association

Executive Officer Change

- **Lisa V. Hunt, RPh, MBA-HM**, has been named executive director of the Wyoming State Board of Pharmacy, replacing Mary K. Walker, who retired in October 2018. Hunt has been a Board staff member since 2015, when she was hired as chief compliance officer. Before joining the Board, Hunt worked as a dispensing pharmacist, ran Oregon's state drug utilization review (DUR) program, and worked for Oregon's, Washington's, and Utah's Medicaid programs, managing the Medicaid DUR, pharmacy and therapeutics committees, and rebate programs. Hunt graduated from Oregon State University, holds a master of business administration in health care management, and is a licensed pharmacist in four states.

Board Member Appointments

- **Khalil "Lynn" Crouse, PharmD, RPh**, has been appointed a member of the Arkansas State Board of Pharmacy. Crouse's appointment will expire June 30, 2024.
- **Nicole Harrington, RPh**, has been appointed a member of the New Hampshire Board of Pharmacy. Harrington's appointment will expire September 6, 2023.
- **Keith Bailey** has been appointed a member of the Newfoundland and Labrador Pharmacy Board. Bailey's appointment will expire May 1, 2021.
- **Shawn Bugden** has been appointed a member of the Newfoundland and Labrador Pharmacy Board. Bugden's appointment will expire May 1, 2021.
- **Brittany Churchill** has been appointed a member of the Newfoundland and Labrador Pharmacy Board. Churchill's appointment will expire May 1, 2020.
- **Mark Sheppard** has been appointed a public member of the Newfoundland and Labrador Pharmacy Board. Sheppard is serving at the discretion of the appointing body.
- **Colleen Squires** has been appointed a member of the Newfoundland and Labrador Pharmacy Board. Squires' appointment will expire May 1, 2020.
- **Shawn Vallis** has been appointed a member of the Newfoundland and Labrador Pharmacy Board. Vallis' appointment will expire May 1, 2019.
- **Henry White** has been appointed a member of the Newfoundland and Labrador Pharmacy Board. White's appointment will expire May 1, 2021.

Board Member Reappointments

- **Taggart Norris** has been reappointed a member of the Newfoundland and Labrador Pharmacy Board. Norris' appointment will expire May 1, 2020.
- **Chad Parsons** has been reappointed a member of the Newfoundland and Labrador Pharmacy Board. Parsons' appointment will expire May 1, 2020.
- **Tom Nelson** has been reappointed a public member of the South Dakota State Board of Pharmacy. Nelson's appointment will expire October 1, 2021.
- **Leonard Petrik, RPh**, has been reappointed a member of the South Dakota State Board of Pharmacy. Petrik's appointment will expire October 1, 2021. ■



Newly Accredited VAWD Facilities

The following facilities were accredited through the NABP Verified-Accredited Wholesale Distributors® (VAWD®) program:

BioRidge Pharma, LLC
Florham Park, NJ

**BluPax Pharmaceuticals, LLC,
dba BluPax Pharma**
Edison, NJ

Cutanea Life Sciences, Inc
Wayne, PA

FedEx Supply Chain, Inc
Olive Branch, MS

Genzyme Corporation
Northborough, MA

GlaxoSmithKline
Colonial Heights, VA
Knoxville, TN

**J M Smith Corporation,
dba Smith Drug Company**
Carey, OH

MAGNA Pharmaceuticals, Inc
Louisville, KY

**Masters Drug Company, Inc,
dba Masters Pharmaceutical;
River City Pharma**
Mason, OH

**Masters Drug Company, Inc,
dba RXTPL**
Mason, OH

Morris & Dickson Co, LLC
Shreveport, LA

A full listing of more than 600 accredited VAWD facilities is available on the NABP website at www.nabp.pharmacy.

Idaho Implements Continuation of Therapy Rule

As of July 1, 2018, an Idaho pharmacist “may refill a prescription for a non-controlled drug one (1) time in a six (6)-month period when the prescriber is not available for authorization. In such cases, a pharmacist may dispense a refill up to the quantity on the most recent fill or a thirty (30)-day supply, whichever is less.” This new continuation therapy rule took effect on July 1, 2018, under Idaho Administrative Code 27.01.03.303.03(b), which can be found at <https://adminrules.idaho.gov/rules/current/27/index.html>.

For more details, see the September 2018 issue of the *Idaho Board of Pharmacy Newsletter* available on the NABP website at www.nabp.pharmacy in the Boards of Pharmacy section.

Kansas Board Requires Nonresident Facilities to Submit New Form With Application

The Kansas State Board of Pharmacy requires all nonresident facilities to submit a new form when applying to the Board. The form, “Non-Resident Information Form S-350,” addresses what the facility plans to ship or has shipped into Kansas. Further, Form S-350 is available under the Supplemental Forms section at <http://pharmacy.ks.gov/resources-consumerinfo/forms>. To learn more, see the Kansas Board of Pharmacy’s September 2018 *Newsletter* available at www.nabp.pharmacy in the Boards of Pharmacy Section.

New Laws Address e-Prescribing, Oversight of Facilities, and CS

The Tennessee Legislature passed several bills that address e-prescribing practices, the rulemaking process for oversight of facilities, and the regulation of controlled substances (CS). Some of the changes are as follows:

- Public Chapter 883 lays the framework for e-prescribing practices in the state and the exceptions from electronic prescriptions. This act requires all Schedule II prescriptions to be e-prescribed by January 1, 2020, except under certain circumstances.
- Public Chapter 1029 requires the Tennessee Board to promulgate rules regarding the Board’s oversight of facilities that manufacture, warehouse, and distribute medical devices. The rulemaking process will include the formation of an advisory committee composed of medical device industry representatives and a representative of the Department of Economic and Community

Development. This act took effect July 1, 2018, and the rulemaking began in September 2018.

- Public Chapter 1040 revises various provisions of the law regarding CS and their analogues and derivatives, including updating identifications of drugs categorized in Schedules I-V. The act, which took effect July 1, 2018, creates an offense for the sale or offer to sell kratom, unless it is labeled and in its natural form. Under the act, it is an offense to distribute, offer for sale, or sell kratom to a person under 21 years of age. Also, it is an offense to purchase or possess kratom if under 21 years of age.

Additional information about these changes as well as other legislative updates can be found on the Tennessee Board of Pharmacy’s September 2018 *Newsletter* available in the Board of Pharmacy section on NABP’s website at www.nabp.pharmacy.

Virginia Board Regulates Production and Dispensing of Cannabidiol or THC-A Oil

On September 25, 2018, the Virginia Board of Pharmacy granted conditional approval (contingent upon criminal background checks) to five pharmaceutical processors to produce and dispense cannabidiol oil or THC-A oil. The law authorizes the Board to issue or renew in any year a maximum of five pharmaceutical processor permits – one for each health service area established by the Virginia Board of Health.

In the Commonwealth of Virginia, a pharmaceutical processor is a facility that operates under pharmacist oversight and has obtained a permit from the Virginia Board of Pharmacy (pursuant to Section 54.1-3408.3) to cultivate cannabis plants for the production and dispensing of cannabidiol oil or THC-A oil. A physician registered with the Board of Pharmacy may issue a written certification for the oils to a patient for treatment or to alleviate the symptoms of any diagnosed condition or disease determined by the physician to benefit from such use. The written certificate provides an affirmative defense for possessing the oils. Patients, along with parents and guardians of minors or incapacitated adults, must also register with the Board.

The application process for the pharmaceutical processor permits will occur in the following three stages: submitting of initial applications, awarding of conditional approvals, and granting of pharmaceutical processor permits. Additional information, including frequently asked questions, laws, and regulations, may be found at www.dhp.virginia.gov/pharmacy/PharmaceuticalProcessing/default.htm. ■

Newsletters of state boards in the NABP State Newsletter Program are available on the NABP website. Five years’ worth of issues are posted on each participating state’s page.

FDA's Final Guidances Address Compounding and Repackaging of Radiopharmaceuticals

On September 26, 2018, Food and Drug Administration (FDA) published the final guidance for industry titled *Compounding and Repackaging of Radiopharmaceuticals by Outsourcing Facilities*. In this final guidance, FDA sets forth its policy regarding compounding and repackaging of radiopharmaceuticals for human use by entities that are registered with FDA as outsourcing facilities. The guidance describes how FDA generally intends to apply section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to radiopharmaceuticals compounded by outsourcing facilities. In addition, the guidance describes the conditions under which FDA generally does not intend to take action for violations of certain provisions of the FD&C Act when an outsourcing facility repackages radiopharmaceuticals, according to the *Federal Register* notice at www.gpo.gov/fdsys/pkg/FR-2018-09-26/pdf/2018-20901.pdf.

At the same time, FDA published the final guidance titled *Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities*. The guidance sets forth FDA's policy regarding compounding and repackaging of radiopharmaceuticals for human use by state-licensed nuclear pharmacies, federal facilities, and other entities that hold a radioactive materials license for medical use issued by the Nuclear Regulatory Commission or by an Agreement State. Because such radiopharmaceuticals are not eligible for exemptions from provisions of the FD&C Act related to the production of drugs, FDA is issuing this guidance to describe the conditions under which it generally does not intend to take action for violations of certain provisions of the FD&C Act when these entities compound or repackage radiopharmaceuticals. More details are available in the *Federal Register* notice at www.gpo.gov/fdsys/pkg/FR-2018-09-26/pdf/2018-20902.pdf.

Biosimilars Added to FIP's Policy on Pharmacists' Right to Substitute a Medication

To account for the emergence of biological medicines and their biosimilars onto the medical landscape, the International Pharmaceutical Federation (FIP) has added biosimilars to its policy on pharmacists' right to substitute one medicine for another. The revised Statement of Policy titled "Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution" includes the core principles of the original statement and the following:

- generic substitution is recommended as part of the pharmacist's dispensing role;
- pharmacists should be provided with bioavailability data by regulatory authorities and manufacturers; and
- a medicine should only be substituted with a product

containing a different active ingredient in agreement with the prescriber.

According to FIP's October 2, 2018, press release, the use of generic names is still encouraged, but the revised statement gives focus to the use of international nonproprietary names. The full Statement of Policy and press release are available at www.fip.org in their respective sections.

Educate Patients About Safe Acetaminophen Use During Cold and Flu Season

During cold and flu season, the Acetaminophen Awareness Coalition encourages health care providers to educate patients about safe acetaminophen use. Almost 50% of acetaminophen overdoses are unintentional and a result of not reading and following the medicine label, according to the Acetaminophen Awareness Coalition's *Know Your Dose* campaign. The campaign offers several tips to share with patients, including:

1. Read and follow the instructions on the label.
2. Know which medicines contain acetaminophen.
3. Take only one medicine at a time that contains acetaminophen.
4. Ask a pharmacist or health care provider about dosing instructions or medicines that contain acetaminophen.

To download or order free patient educational materials, including posters, flyers, and talking points, visit www.knowyourdose.org.

FDA Offers CE Course on Reducing Hypoglycemic Events in Patients With Type 2 Diabetes

FDA is offering a free, one-hour continuing education (CE) course for health care providers (physicians, pharmacists, nurses, and others) about the reduction of hypoglycemic events in patients with Type 2 diabetes. The course, *Leveraging Health Literacy and Patient Preferences to Reduce Hypoglycemic Events in Patients with Type 2 Diabetes*, will describe the prevalence of hypoglycemic events and identify risk factors leading to an event. Available for credit through October 31, 2020, this course will introduce methods of assessing health literacy and numeracy of patients and caregivers; review effective ways to incorporate patient preferences into care plans; and list action steps to reduce the likelihood of a hypoglycemic event for high-risk patients. To participate in this CE course, visit <http://fdapasediabetes.e-paga.com>.

The FDA CDER is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This program meets the criteria for one contact hour (0.1 CEU) of CPE credit. The ACPE Universal Activity Number for this knowledge-based activity is 0453-9999-17-449-H01-P. Further, FDA's CDERLearn in the Center for Drug Evaluation and Research (CDER) offers a variety of learning opportunities at www.fda.gov/Training/ForHealthProfessionals/ucm545645.htm. ■



INNOVATIONS[®]

National Association of Boards of Pharmacy
1600 Feehanville Drive
Mount Prospect, IL 60056

First Class
U.S. POSTAGE
PAID
Permit #583
Schaumburg, IL 60173

UPCOMING EVENTS

Committee on Law Enforcement/ Legislation

January 23-24, 2019
NABP Headquarters

Committee on Constitution and Bylaws

April 8, 2019
Teleconference

NABP 115th Annual Meeting

May 16-18, 2019
Minneapolis, MN

FPGEE Administration

April 10, 2019

NEVER MISS A MINUTE. FOLLOW US ON SOCIAL.

